A Phase II Study to Evaluate Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH and GM-CSF Following the Anti-CD20 Antibody, Rituximab, in Previously Treated Patients With Follicular Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2013
At a glance
- Drugs GTOP 99; Rituximab; Sargramostim
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 12 May 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 07 Nov 2005 New trial record.